High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/C model of infection

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Sánchez Sampedro, Lucas ^a   Gómez, Carmen Elena ^a   Mejías Pérez, Ernesto ^a   Sorzano, Carlos Oscar ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 2; L SELECTIN; PEPTIDE VACCINE; PHENYLALANYLSERYLPROLYLSERYLLEUCYLGLUTAMICYLHISTIDYLPROLYLISOLEUCYLVALYLVALYLSERYLGLYCYLSERYLTRYPTOPHYLASPARTYLASPARAGINE; PROTEIN LACK; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL POPULATION; CELL STIMULATION; DNA VECTOR; DRUG SYNTHESIS; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL PARAMETERS; INFECTION CONTROL; LEISHMANIA MAJOR; LEISHMANIASIS; MEMORY CELL; MOUSE; NONHUMAN; PROVOCATION TEST; VACCINATION;

EID: 84862015359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038859     Document Type: Article

References (48)

1. World Health O (2004) Scientific Working Group Report on Leishmaniasis. TDR Research Publications.
2. Croft SL, Olliaro P, (2011) Leishmaniasis chemotherapy-challenges and opportunities. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 17: 1478 1483.
3. Duthie MS, Raman VS, Piazza FM, Reed SG, (2011) The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 30(2): 134 141.
4. Ahmed SBH, Bahloul C, Robbana C, Askri S, Dellagi K, (2004) A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 22: 1631 1639.
5. Mougneau E, Altare F, Wakil aE, Zheng S, Coppola T, (1995) Expression cloning of a protective Leishmania antigen. Science 268: 563 566.
6. Melby PC, Yang J, Zhao W, Perez LE, Cheng J, (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69: 4719 4725.
7. Launois P, Maillard I, Pingel S, Swihart KG, Xénarios I, (1997) IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6: 541.
8. Julia V, Rassoulzadegan M, Glaichenhaus N, (1996) Resistance to Leishmania major induced by tolerance to a single antigen. Science 274: 421 423.
9. Seder Ra, Darrah Pa, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nature reviews Immunology 8: 247 258.
10. Faria DR, Souza PE, Duraes FV, Carvalho EM, Gollob KJ, (2009) Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol 31: 432 439.
11. Nateghi Rostami M, Keshavarz H, Edalat R, Sarrafnejad A, Shahrestani T, (2010) CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis. PLoS Negl Trop Dis 4: e845.
12. Xin L, Wanderley JL, Wang Y, Vargas-Inchaustegui DA, Soong L, (2011) The magnitude of CD4(+) T-cell activation rather than TCR diversity determines the outcome of Leishmania infection in mice. Parasite Immunol 33: 170 180.
13. Keesen TS, Antonelli LR, Faria DR, Guimaraes LH, Bacellar O, (2011) CD4(+) T cells defined by their Vbeta T cell receptor expression are associated with immunoregulatory profiles and lesion size in human leishmaniasis. Clin Exp Immunol 165: 338 351.
14. Khamesipour A, Rostami MN, Tasbihi M, Mohammadi AM, Shahrestani T, (2012) Phenotyping of circulating CD8(+) T cell subsets in human cutaneous leishmaniasis. Microbes Infect doi:10.1016/j.micinf.2012.1002.1006.
15. Darrah Pa, Patel DT, De Luca PM, Lindsay RWB, Davey DF, (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature medicine 13: 843 850.
16. Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207: 1421 1433.
17. Ramos I, Alonso A, Peris A, Marcen JM, Abengozar MA, (2009) Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection. Vaccine 27: 6695 6703.
18. Papadogiannakis E, Andritsos G, Kontos V, Spanakos G, Koutis C, (2010) Determination of CD4+ and CD8+ T cells in the peripheral blood of dogs with leishmaniosis before and after prolonged allopurinol monotherapy. Vet J 186: 262 263.
19. Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M, (2006) MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes and infection 8: 810 822.
20. Ramos I, Alonso a, Marcen JM, Peris a, Castillo Ja, (2008) Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26: 333 344.
21. Perfetto SP, Chattopadhyay PK, Roederer M, (2004) Seventeen-colour flow cytometry: unravelling the immune system. Nature reviews Immunology 4: 648 655.
22. Launois P, Pingel S, Himmelrich H, Locksley R, Louis J, (2007) Different epitopes of the LACK protein are recognized by V beta 4 V alpha 8 CD4+ T cells in H-2b and H-2d mice susceptible to Leishmania major. Microbes and infection 9: 1260 1266.
23. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, (2011) Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 153: 154 162.
24. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201: 95 104.
25. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D, (2005) Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73: 5286 5289.
26. Tapia E, Pérez-Jiménez E, López-Fuertes L, Gonzalo R, Gherardi MM, (2003) The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes and infection 5: 73 84.
27. Ramos I, Alonso a, Peris a, Marcen JM, Abengozar Ma, (2009) Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection. Vaccine 27: 6695 6703.
28. Launois P, Maillard I, Pingel S, Swihart KG, Xenarios I, (1997) IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6: 541 549.
29. Reiner SL, Fowell DJ, Moskowitz NH, Swier K, Brown DR, (1998) Control of Leishmania major by a monoclonal alpha beta T cell repertoire. J Immunol 160: 884 889.
30. Pingel S, Launois P, Fowell DJ, Turck CW, Southwood S, (1999) Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. J Exp Med 189: 1111 1120.
31. Liew FY, Li Y, Millott S, (1990) Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. Journal of immunology 145: 4306 4310.
32. Bogdan C, Moll H, Röllinghoft M, (1990) Tumor necrosis factor-a in combination with intederon, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. European journal of immunology pp. 1131 1135.
33. Green SJ, Crawford RM, Hockmeyer JT, Meltzer MS, Nacy CA, (1990) Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol 145: 4290 4297.
34. Liew FY, Yang YLIJDM, Severn A, Wellcome FEGCOX, (1991) TNF-a reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis. Immunology 39: 304 309.
35. Cote-Sierra J, Bredan A, Toldos CM, Stijlemans B, Brys L, (2002) Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect Immun 70: 240 248.
36. Haque A, Stanley AC, Amante FH, Rivera Fde L, Zhou Y, (2010) Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity. J Immunol 184: 2583 2592.
37. Wilhelm P, Ritter U, Labbow S, Donhauser N, Rollinghoff M, (2001) Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J Immunol 166: 4012 4019.
38. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW, (2000) Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 68: 6289 6293.
39. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, (2011) CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187: 1347 1357.
40. Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araujo AF, (2011) Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun 79: 2120 2130.
41. Macedo AB, Sanchez-Arcila JC, Schubach AO, Mendonca SC, Marins-Dos-Santos A, (2012) Multifunctional CD4 T cells in patients with American cutaneous leishmaniasis. Clin Exp Immunol 167: 505 513.
42. Ferlin WG, von der Weid T, Cottrez F, Ferrick DA, Coffman RL, (1998) The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur J Immunol 28: 525 531.
43. Gherardi MM, Pérez-Jiménez E, Nájera JL, Esteban M, (2004) Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. Journal of immunology 172: 6209 6220.
44. Ramsay aJ, Leong KH, Ramshaw Ia, (1997) DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunology and cell biology 75: 382 388.
45. Gonzalez-Aseguinolaza G, Taladriz S, Marquet a, Larraga V, (1999) Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. European journal of biochemistry/FEBS 259: 909 916.
46. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, (2008) Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 82: 2975 2988.
47. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M, (2010) Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5: e12395.
48. Najera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M, (2010) Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5: e11406.